Adipose Tissue Remodeling in Obesity: An Overview of the Actions of Thyroid Hormones and Their Derivatives

pmc Pharmaceuticals (Basel) Pharmaceuticals (Basel) 2102 pharmaceuticals pharmaceuticals Pharmaceuticals 1424-8247 Multidisciplinary Digital Publishing Institute (MDPI) PMC10146771 PMC10146771.1 10146771 10146771 37111329 10.3390/ph16040572 pharmaceuticals-16-00572 1 Review Adipose Tissue Remodeling in Obesity: An Overview of the Actions of Thyroid Hormones and Their Derivatives Petito Giuseppe 1 † Cioffi Federica 2 † Magnacca Nunzia 1 https://orcid.org/0000-0002-5256-3599 de Lange Pieter 1 https://orcid.org/0000-0003-1571-0980 Senese Rosalba 1 * Lanni Antonia 1 Asim Ejaz Academic Editor 1 Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “L. Vanvitelli”, 81100 Caserta, Italy 2 Department of Sciences and Technologies, University of Sannio, 82100 Benevento, Italy * Correspondence: rosalba.senese@unicampania.it ; Tel.: +39-0823-27-4580 † These authors contributed equally to this work. 10 4 2023 4 2023 16 4 434554 572 21 3 2023 04 4 2023 07 4 2023 10 04 2023 29 04 2023 01 05 2023 © 2023 by the authors. 2023 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ ). Metabolic syndrome and obesity have become important health issues of epidemic proportions and are often the cause of related pathologies such as type 2 diabetes (T2DM), hypertension, and cardiovascular disease. Adipose tissues (ATs) are dynamic tissues that play crucial physiological roles in maintaining health and homeostasis. An ample body of evidence indicates that in some pathophysiological conditions, the aberrant remodeling of adipose tissue may provoke dysregulation in the production of various adipocytokines and metabolites, thus leading to disorders in metabolic organs. Thyroid hormones (THs) and some of their derivatives, such as 3,5-diiodo-l-thyronine (T2), exert numerous functions in a variety of tissues, including adipose tissues. It is known that they can improve serum lipid profiles and reduce fat accumulation. The thyroid hormone acts on the brown and/or white adipose tissues to induce uncoupled respiration through the induction of the uncoupling protein 1 (UCP1) to generate heat. Multitudinous investigations suggest that 3,3′,5-triiodothyronine (T3) induces the recruitment of brown adipocytes in white adipose depots, causing the activation of a process known as “browning”. Moreover, in vivo studies on adipose tissues show that T2, in addition to activating brown adipose tissue (BAT) thermogenesis, may further promote the browning of white adipose tissue (WAT), and affect adipocyte morphology, tissue vascularization, and the adipose inflammatory state in rats receiving a high-fat diet (HFD). In this review, we summarize the mechanism by which THs and thyroid hormone derivatives mediate adipose tissue activity and remodeling, thus providing noteworthy perspectives on their efficacy as therapeutic agents to counteract such morbidities as obesity, hypercholesterolemia, hypertriglyceridemia, and insulin resistance. adipose tissues thyroid hormones 3,5 diiodo-L-thyronine browning metabolic disease obesity University of Campania “L. Vanvitelli” This research was financially supported by a grant from the University of Campania “L. Vanvitelli” and by the VALERE project from the University of Campania “L. Vanvitelli”. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY 1. Introduction The prevalence of obesity is well acknowledged worldwide as a major health issue. Due to changes in food composition and sedentary lifestyles in Western societies, obesity has reached epidemic proportions [ 1 ]. Excessive weight gain causes an increased risk of several diseases, mostly cardiovascular diseases (CVDs), type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), and cancer [ 2 , 3 , 4 ]. White adipose tissue (WAT) is the main storage site for excess calorie intake [ 5 ]. It ensures the survival of an organism during long periods of fasting [ 6 ]. It is also an organ that is able to respond rapidly and dynamically to nutrient deprivation and excess through adipocyte hypertrophy and hyperplasia [ 7 ]. In obese individuals, WAT exhibits reduced angiogenesis, excessive production of extracellular matrix (ECM), increased infiltration of immune cells, and consequent pro-inflammatory responses [ 8 ]. The remodeling of WAT is a continuous process that is pathologically accelerated in the state of obesity. In mammals, including humans, another major type of adipose tissue (AT), namely brown adipose tissue (BAT), is present in addition to WAT. Unlike white fat, the BAT is a specialized tissue for non-shivering thermogenesis (NST) to dissipate energy as heat, thereby playing a key role in the energetic homeostasis of the entire body. Thyroid hormones (THs) and their derivatives exert numerous functions in many tissues, including the activation and remodeling of AT. THs contribute significantly to brown adipocyte thermogenesis, and in white adipose depots, THs are also able to induce brown adipocyte recruitment, known as “browning”. The browning of WAT is certainly worthy of in-depth analysis to promote targeted therapeutic weight loss [ 9 , 10 ]. Herein, we summarize our current knowledge regarding the mechanism by which THs and their derivatives mediate AT activity and remodeling. This review provides relevant information on their potential use as therapeutic agents for the treatment of obesity and associated diseases. 2. Types of Adipose Tissue AT plays a critical role in regulating body metabolism and homeostasis. Unlike other organs and tissues, AT can expand to accommodate excess energy in the form of accumulated lipids, distinguishing it from other organs and tissues [ 11 ]. AT is divided into two major types, WAT and BAT. Most of the WAT deposits are widely characterized as visceral (vWAT) or subcutaneous (sWAT) [ 12 ]. vWAT is further subdivided into mesenteric, omental, perirenal, and peritoneal deposits [ 13 ] ( Figure 1 ). Alternatively, BAT is a thermogenic tissue specialized in the conversion of lipids into heat. It is indeed perfused by an extensive network of blood capillaries and highly innervated by noradrenergic fibers [ 14 ]. In addition to WAT and BAT, a third type of adipocyte has been described, termed “beige”, or “brite” (brown-in-white) [ 15 ]. In this tissue, white adipocytes show high plasticity and possess multiple similarities to brown adipocytes. Beige adipocytes are fundamental in weight control, energy balance regulation, and amelioration of glucose and lipid metabolism [ 9 ]. A growing body of evidence indicates that pathophysiological conditions such as obesity and aberrant remodeling of AT can induce dysregulation in the production of various adipocytokines, hormones, and metabolites, thus resulting in metabolic disorders [ 16 ]. 3. WAT WAT comprises adipocytes, which are bound by loose, vascularized, and innervated connective tissue. In white adipocytes, a large “unilocular” lipid droplet occupies more than 90% of the cell volume. Additionally, a thin layer of cytoplasm containing other organelles is present [ 17 ]. WAT plays an endocrine role as well as exerting a metabolic function. The metabolic functions include lipogenesis, fatty acid oxidation, and lipolysis, while adipokines are produced by the endocrine system. During fasting periods, WAT supplies fuel to the organism by storing and releasing highly energetic molecules, particularly fatty acids. The balance between lipid synthesis and fatty acid oxidation, as well as fatty acid release, is essential for adipocyte function [ 18 ]. Adipocytes secrete a variety of mediators, including exosomes, miRNAs, lipids, inflammatory cytokines, and peptide hormones [ 19 , 20 ]. However, numerous investigations have been conducted as regards the secretion of hormones by WAT. Among these hormones are leptin, adiponectin, and resistin which regulate food intake, the reproductive axis, insulin sensitivity, and immune responses. It has been shown that dysregulation of any of these hormones can lead to systemic metabolic dysfunction, as well as chronic metabolic diseases and several cancers [ 21 ]. 4. Hypertrophic and Hyperplasic WAT Expansion Metabolic syndrome/obesity is currently considered a burdensome and important health issue that may prompt the occurrence of related pathologies such as T2DM, hypertension, and cardiovascular disease (CVD). It is widely recognized that metabolic disorders are multifactorial pathologies in which nutrient excesses are closely related to the activation of the innate immune system in most organs responsible for maintaining energy balance [ 22 ]. In the presence of a positive energy balance, there is an increase in demand for lipid storage, which can be accommodated either by increasing adipocyte size (hypertrophy) or by increasing the number of adipocytes (hyperplasia) [ 23 ]. Adipocyte hypertrophy and hyperplasia are regulated by environmental and genetic factors [ 24 ]. According to some research, obesity is associated with an increase in dead adipocytes, which impair AT function and promote subsequent inflammation. In hypertrophic adipocytes, pro-inflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1), are expressed and secreted [ 25 ]. An increase in pro-inflammatory cytokines leads to insulin resistance and inflammation of AT due to the recruitment of macrophages and T cells [ 26 , 27 ]. Moreover, increased adipose mass is associated with hypoxia [ 28 ]. Activation of hypoxia-inducible factor 1α (HIF-1α), a key transcription factor mediating hypoxic responses, accelerates adipose tissue fibrosis. Alternately, hyperplasia is observed. The remodeling of AT involves reversible changes in the composition of immune cells and the size of adipocytes, altering numerous AT functions. Adipose tissue-activated macrophages (ATMs) polarize in response to changes in their environment, forming M1 and M2 macrophage phenotypes [ 29 ]. AT inflammation and insulin resistance (IR) in the whole body are initiated and maintained by classically activated M1 macrophages [ 30 ]. A large number of inflammatory cytokines, including IL-6, interleukin 1β (IL-1β), and MCP-1, are produced by macrophages that infiltrate the target organ under the condition of obesity. These cytokines negatively influence the transmission of insulin signals and increase the development of chronic inflammation and IR [ 31 , 32 , 33 ]. The M2 phenotype is, however, mainly responsible for anti-inflammatory responses and maintaining tissue homeostasis [ 34 ]. In general, M1 macrophages are mainly induced by Th1 signaling. On the other hand, M2 macrophages are induced by Th2 signaling and release arginase-1, interleukin 10 (IL-10), interleukin 4 (IL-4), interleukin 13 (IL-13), ornithine, and polyamines, promoting proliferation, tissue repair, and immune tolerance [ 35 ]. It is estimated that more than 90% of ATMs in healthy AT are of the M2 phenotype containing anti-inflammatory properties [ 36 ]. 5. BAT In the last two decades, positron emission tomography scans have revealed that metabolically active BAT exists in specific regions of adult humans. The amount of this tissue correlates positively with resting metabolic rate and negatively with body mass index [ 37 ]. BAT is characterized by multilocular lipid droplets; high mitochondrial density, which contributes to its coloration; and high expression of uncoupling protein 1 (UCP1). BAT is mainly located in the interscapular (iBAT) and subscapular (sBAT) regions of adult mice. In addition, small deposits of BAT are found deep between the scapula and the head (cervical BAT (cBAT)), around the aorta in the thoracic cavity (mediastinal BAT (mBAT)), and around the kidney (perirenal BAT (pBAT)). iBAT is the most widely used depot for the study of BAT function in mice [ 38 ]. The main role of BAT is to maintain a constant body temperature by generating heat. Unlike WAT, BAT is involved in non-shivering thermogenesis, a process that produces heat either through mitochondrial respiration uncoupling dependent on UCP1 or through a UCP1-independent mechanism [ 39 ]. Compared to white adipocytes, which contain a single lipid droplet, brown adipocytes contain many smaller droplets and a substantial number of mitochondria. In addition, brown fat contains more capillaries than white fat; capillaries supply oxygen and nutrients to the tissues and distribute heat throughout the body. BAT cells derive from a muscle-like Myf5+ cell line. PR domain containing 16 (PRDM16) controls the determination between brown fat and muscle between days 9 and 12 of pregnancy [ 40 , 41 ]. As previously mentioned, heat production is due to a UCP1 protein found almost exclusively in brown adipocytes. Additionally, diet-induced obesity is associated with decreased UCP1 expression and BAT thermogenesis [ 42 ]. During its active phase, BAT is able to absorb large quantities of lipids, glucose, and lactate from circulation, thereby affecting triglyceride levels as well as glucose concentrations in the blood, playing a fundamental role in metabolic homeostasis [ 43 ]. However, recent data suggest that BAT may play an endocrine role through the release of endocrine factors. Under conditions of thermogenic activation, brown fat releases several endocrine signaling molecules [ 44 ]. Although the endocrine role of BAT is still unknown, accumulating evidence indicates that BAT releases factors that act with both autocrine and paracrine action. These include vascular endothelial growth factor-A (VEGF-A), which probably promotes angiogenesis in response to sympathetic nervous system activation, insulin-like growth factor-I (IGF-I), and fibroblast growth factor-2 (FGF2) promoting an increase in the density of brown adipocyte precursor cells [ 45 ]. In BAT depots, thyroxine can be converted into 3,3′,5-triiodothyronine (T3) through the presence of type II 5′-deiodinase (BAT 5′D-II). Locally generated T3 contributes to the intracellular pathways of thermogenic activation of brown adipocytes [ 46 ]. Compared to white fat, BAT is less susceptible to developing local inflammation in response to obesity. Fitzgibbons TP et al. demonstrated that the BAT of obese mice exhibits significantly lower macrophage infiltration and immune cell-enriched mRNA expression than WAT, suggesting that this tissue “resists” obesity-induced inflammation [ 47 ]. Research studies have shown that mice fed a long-term HFD had elevated levels of inflammation markers such as TNF-α and EGF-like module-containing mucin-like hormone receptor-like 1 (F4/80). However, the increased levels of pro-inflammatory cytokines were mainly associated with the presence and activity of infiltrating pro-inflammatory immune cells [ 48 , 49 ]. 6. Beige Adipose Tissue (BeAT) In addition to WAT and BAT, a third type of adipocyte has been described, termed “beige”, or “brite” (brown-in-white). Similar to brown adipocytes, these are multilocular cells with moderate mitochondrial content and inducible expression of UCP1 [ 50 ]. The beige adipocytes arise from Myf 5-negative (Myf 5-) precursors [ 15 , 51 ]. It has been shown that some beige adipocytes express myosin-heavy chain 11 (Myh11), a selective marker of smooth muscles [ 51 ]. Recent findings have suggested that beige cells could originate from the transdifferentiation of white fat cells [ 52 , 53 ]. However, it is not clear whether this conversion involves a cell type with this specific predisposition. Therefore, several studies have been conducted to demonstrate that different WAT depots bear different browning capacities that most likely resort to alternative mechanisms to originate beige cells [ 54 , 55 , 56 ]. As observed in obesity, the infiltration of immune cells in the sWAT alters the ability of precursor cells to differentiate into active beige adipocytes and creates a deleterious inflammatory microenvironment involving TNF-α, interferon-c (IFN-c), and interleukin 17 (IL-17) [ 57 ]. Similarly to BAT, BeAT affects the entire body’s energy balance, and numerous investigations are underway to develop novel treatments for obesity and related complications. Loss of BeAT leads to obesity susceptibility [ 58 ]; indeed, when exposed to cold or activated by beta-adrenergic receptors (β-ARs), beige adipocytes can be detected in WAT. This phenomenon is known as the “browning of WAT” [ 59 , 60 ]. As indicated previously, BAT plays a key role in thermogenesis, contributing to energy consumption and the prevention of obesity. In addition to classic BAT activation for treating obesity and T2DM, the recruitment of beige adipocytes has received much attention in recent years. This could represent a novel therapeutic target for obesity and T2DM. Beige adipocytes are also crucial in weight control, energy balance regulation, and amelioration of glucose and lipid metabolism. External stimuli (cold exposure, β-adrenergic agonists, etc.) accelerate beige adipocyte recruitment by WAT, resulting in increased energy consumption and thermogenesis. The consumption of glucose and lipids indirectly improves glucose tolerance, insulin sensitivity, and beta-cell function [ 61 , 62 ]. 7. Pink Adipose Tissue Pink adipocytes are an alternative class of adipocytes that has recently generated interest in the scientific world. Pink adipocytes are alveolar epithelial cells of the mammary gland that produce and secrete milk for the nourishment of the pups [ 63 ]. It has been hypothesized that they derive from subcutaneous white adipocytes that have transdifferentiated [ 64 ]. It has also been observed that post-lactational pink adipocytes may trans-differentiate into brown adipocytes [ 65 ]. 8. Thyroid Hormones and AT 8.1. Thyroid Hormone Biosynthesis and Actions: The Effect of 3,5,3′-Triiodo-L-thyronine (T3) on AT The primary product of the thyroid is 3,5,3′,5′-tetraiodo-L-thyronine (T4), which is synthesized at three “hormonogenic sites” on the thyroglobulin chain. Despite exhibiting certain biological activities, T4 is a precursor to the active hormone, T3 [ 66 ]. In target tissues, T4 is also converted to T3 by type I 5′-deiodinase (D1) and type II 5′-deiodinase (D2). Further deiodination of circulating T4 and T3 produces TH derivatives that bind poorly to thyroid receptors (TRs). From T4, type III 5-deiodinase (D3) generates 3,3′,5′-triiodothyronine (reverse T3) and 3,3′-diiodo-l-thyronine (3,3′-T2). Together, the deiodination processes of T3 and rT3 give rise to different diiodothyronines and monoiodothyronines that are present in trace concentrations in the sera [ 67 ]. THs are hormones that affect almost all cells of the human body. Generally, THs increase metabolic rate and thus thermogenesis by binding their intranuclear receptor. Increased metabolic rate results in a greater consumption of oxygen and energy [ 68 ]. The effects of THs on target cells are exerted by different pathways, which can be subdivided into “genomic” and “nongenomic” actions [ 69 ]. The genomic actions of THs are initiated in the cell nucleus via TRs. T3 receptors are ligand-activated transcription factors. TRs can interact with thyroid-hormone response elements (TREs) as protein dimers, heterodimerizing with another member of the nuclear receptor family or with retinoic acid receptors (RXRs), or self-homodimerizing. In addition to the conventional effects of transcriptional regulation via TRs, THs exhibit a remarkably rapid action on cells which may be initiated outside the nucleus and involve a variety of signal transduction pathways (non-genomic action) [ 69 ]. The sites of nongenomic actions are distributed throughout various cellular compartments, including the plasma membrane, cytoplasm, cytoskeleton, and subcellular organelles (such as mitochondria) [ 70 , 71 , 72 , 73 ]. Membrane receptors, consisting of specific integrin αv/β3 receptors, have been identified and found to mediate actions at multiple sites [ 74 , 75 ]. 8.2. The Effect of 3,5,3′-Triiodo-L-thyronine (T3) on AT THs exert pleiotropic actions, and AT is an important target of these hormones [ 76 ]. Panveloscki-Costa et al. have demonstrated the beneficial effects of T3 treatment of obese rats on the improvement of insulin sensitivity and on the negative modulation of inflammatory state in epididymal and mesenteric AT. Therefore, this study showed that T3 treatment reduces adiposity and increases the lean mass of obese rats. T3 also acts as an immunomodulatory agent reducing the content of inflammatory cytokines in the AT and promoting a phenotypic switch in AT macrophage polarization [ 77 ]. In an alloxan-induced diabetic rat model, T3 treatment (1.5 µg per 100 g BW) reduced serum TNF-α and epidydimal WAT (eWAT) expression of IL-6 and TNF-α. Additionally, treatment with T3 decreased serum levels of chemokine (C-C motif) ligand 2 (Ccl2) and F4/80 and expression levels of cluster of differentiation 68 (CD68) in eWAT. This condition leads to a reduction in immune cell infiltration [ 78 ]. As a thermogenic hormone, T3 is essential for a full metabolic response of BAT under maximal demands [ 79 , 80 , 81 ]. THs can stimulate BAT directly, through TRs expressed in brown adipocytes, and indirectly, through TRs expressed in hypothalamic neurons. THs act on brown adipocyte thermogenesis by increasing the stimulatory action of norepinephrine (NE), as well as enhancing the cyclic adenosine monophosphate (cAMP)-mediated acute rise in UCP1 gene expression ( Figure 2 ) [ 82 ]. Recently, studies have revealed that thyroid hormones can also induce facultative thermogenesis through central mechanisms, as central hyperthyroidism is able to directly activate BAT in a manner dependent on AMP-activated protein kinase (AMPK) and induces browning in mice [ 83 , 84 ]. In brown adipose tissue, T3 stimulates thermogenesis by induction metabolic inefficiency through the activation of the mitochondrial UCP1 [ 80 , 85 ]. Similar to the liver or pituitary, BAT exhibits a high number of TRs [ 86 ]. There are two TR genes, thyroid hormone receptor α (TRα) and thyroid hormone receptor β (TRβ), which are differentially expressed during development and in adult tissues [ 87 , 88 ]. TRα has three splice products. TRα1 is located primarily in the brain, heart, and skeletal muscles and binds to T3. TRα2 and TRα3 splice products are non-T3-binding with several truncated variants [ 87 ]. TRβ has three major T3-binding splice products: TRβ1 is widely expressed; TRβ2 is mainly expressed in the brain, retina, and inner ear; and TRβ3 is widely expressed in the kidney, liver, and lung [ 87 , 89 ]. Both isoforms are required for adequate adaptive thermogenesis in BAT. T3-regulated UCP1 mRNA expression is mediated by TRβ, while TRα1 maintains brown adipocyte adrenergic responsiveness [ 90 ]. Mice with global deletion of TRα1, TRβ, or TRα isoforms showed cold intolerance associated with impaired BAT thermogenesis [ 86 ]. In brown adipocytes, DIO2 regulates local T3 levels. In mature brown adipocytes, D2-expressing cells produce high levels of T3 and activate thyroid hormone receptors [ 91 ]. The lack of adipose DIO2 causes abnormal lipid metabolism in BAT that subsequently leads to cold intolerance [ 92 ]. According to Martinez-Lopez et al., cold exposure at 4 °C induces lipophagy and mitophagy in BAT, suggesting that autophagy is required for adaptive thermogenesis [ 93 , 94 ]. Based on these findings, other researchers investigated whether T3 has a cell-autonomous role in BAT activation by examining autophagy, mitochondrial turnover, fatty acid metabolism, and mitochondrial respiration. The results suggest that T3 increases mitochondrial autophagy (mitophagy) and biogenesis to maintain mitochondrial quality control (MQC) [ 95 ]. Apart from regulating mature brown adipocytes’ thermogenic capacity directly or through the sympathetic nervous system (SNS), T3 can stimulate the hyperplastic growth of iBAT [ 96 ]. 8.3. The Effect of 3,5,3′-Triiodo-L-thyronine (T3) on “Browning” Recent research by Shengnan Liu et al. has demonstrated that T3 can promote adipocyte progenitor cell (APC) proliferation in the iBAT depot of mice. Considering that TRα mediates the T3 effect on APC proliferation in the iBAT depot, further analysis suggests that T3 promotes cell state transition and cell cycle progression via c-Myc in APCs [ 97 ]. Such effects of THs on BAT are well known; however, an alternative mechanism, the so-called “browning” of WAT, has been acknowledged as effectively supporting THs in energy expenditure. In an in vitro model of differentiated human multipotent adipose-derived stem cells (hMADSs), T3 treatment induced UCP-1 expression and mitochondrial biogenesis accompanied by the induction of PGC-1 (peroxisome proliferator-activated receptor-γ coactivator-1α) and NRF1 (nuclear respiratory factor 1). Such impacts of T3 on UCP-1 induction were dependent on TRs [ 98 ]. Moreover, in obese individuals, a reduction of the browning process in WAT was observed. Matesanz et al. demonstrated that the expression of the MAPK kinase 6 (MKK6) is increased in the WAT of obese individuals and reported that in knockout animals, the deletion of MKK6 increases T3-stimulated UCP1 expression in adipocytes, thereby enhancing their thermogenic capacity [ 99 ]. Another study by Miriane de Oliveira et al. showed that, in addition to improving UCP1 expression, T3 treatment improved lipid profile, oxidative stress, and DNA damage in human subcutaneous preadipocytes [ 100 ]. Activating BAT or “browning” of the WAT is therefore considered a promising therapeutic approach for treating obesity and metabolic disorders. In addition, very recently, Ma et al. have demonstrated that systemic administration of T3 affects both inguinal white adipose tissue (iWAT) and whole-body metabolism. They showed that TRβ is the major TR isoform that mediates the T3 action on multiple metabolic pathways in iWAT, including glucose uptake and usage, de novo fatty acid synthesis, and both UCP1-dependent and -independent thermogenesis [ 101 ]. 9. 3,5-Diiodo-L-thyronine (T2) and Its Multiple Biological Effects on AT 9.1. 3,5-Diiodo-L-thyronine (T2), a Thyroid Hormone Derivative with Potent Metabolic Effects Recently, evidence has emerged that some TH metabolites, previously considered inactive products of thyroid hormone metabolism, possess biological activities which include 3,5-T2, a compound that has been a focal point of our previous studies [ 102 , 103 ]. This metabolite manifests some effects of TH within one hour of administration, and mitochondria are considered a direct target of 3,5-T2 [ 104 , 105 ]. It has been reported that T2 has T3-like effects in the absence of thyrotoxic side effects, at least when used at low concentrations [ 106 , 107 , 108 , 109 ]. According to several studies, 3,5-T2 exerts significant biological effects in a variety of tissues, such as the liver, skeletal muscle, heart, and AT [ 102 , 110 , 111 ]. In hypothyroid rats, the administration of 3,5-T2 increased the resting metabolic rate [ 112 ], cold tolerance [ 113 ], and the ability to use lipids as metabolic substrates [ 114 ]. It has also been observed that chronic administration of 3,5-T2 to rats fed an HFD prevented body weight gain, liver adiposity, hypercholesterolemia, and hypertriglyceridemia, while concomitantly preserving muscle glucose uptake and insulin sensitivity [ 115 , 116 , 117 , 118 ]. In addition, in vivo studies show that 3,5-T2 exerts metabolically favorable effects on AT. 9.2. The Effect of 3,5-Diiodo-L-thyronine (T2) on BAT Similarly to T3, 3,5-T2 affects BAT thermogenesis. It improves survival in the cold of hypothyroid rats, increases the oxidative potential of the cell directly binding to cytochrome c oxidase (COX), and induces an increase in mitochondrial biogenesis [ 119 ]. A study conducted by Lombardi et al. found that the intraperitoneal administration of 3,5-T2 to hypothyroid rats housed at thermoneutrality reversed the “white-like” appearance of brown adipocytes in such animals and increased the proportion of multilocular versus unilocular cells in such animals. In addition, 3,5-T2 decreases the diameter of lipid droplets (LDs) and increases mitochondrial content, indicating activation of the BAT [ 120 ]. 3,5-T2 also increases the cellular number of nerve fibers, suggesting that such a part of the thermogenic effect induced by this iodothyronine in BAT is due to sympathetic nervous system (SNS) activation. Moreover, in T2-treated animals, BAT vascularization was higher due to sympathetic activation, since adrenergic stimulation induces VEGF production [ 120 , 121 ]. 9.3. The Effect of 3,5-Diiodo-L-thyronine (T2) on “Browning” Interestingly, it has been demonstrated that 3,5-T2 can induce browning sWAT of rats housed at thermoneutrality [ 122 ]. The ability of 3,5-T2 to affect thermogenesis may also be related to changes in adipocyte morphology and functionality. A browning process has also been reported in a section of anterior sWAT of HFD-T2 rats in which several white adipocytes changed their phenotype. As a result of this transformation, the adipocyte acquires a multilocular phenotype as opposed to a conventional unilocular phenotype, displaying immunoreactivity for UCP1. This process involves different pathways, including microRNAs (e.g., miR-133a and miR-196a) and irisin [ 122 ]. 9.4. The Effect of 3,5-Diiodo-L-thyronine (T2) on vWAT Changes in AT mass and adipocyte volume are known to provoke broad metabolic consequences [ 123 ]. Recently, the effects of 3,5-T2 on vWAT of HFD rats have also been studied by proteomic analysis. Silvestri et al. demonstrated that 3,5-T2 promoted visceral adipose lipolysis through hormone-sensitive lipase (HSL) activation when administered simultaneously to rats treated with HFD (within 1 day after administration), while long-term treatment with 3,5-T2 affected adipocyte morphology (measurable after only 2 weeks and persistent to treatment), tissue vascularization, and the protein profile. In fact, 4 weeks of 3,5-T2 administration prevented HFD-induced hypertrophy and improved vVAT vascularization, suggesting that this iodothyronine may have proangiogenic properties contributing to its insulin-sensitizing properties [ 124 ]. Even more recently, an anti-inflammatory effect exerted by 3,5-T2 on vWAT of rats fed a long-lasting HFD (14 weeks) has been shown by Petito et al. Furthermore, they demonstrated that 3,5-T2 was able to induce a switch from M1 macrophages to M2 macrophages. In addition, the decrease in cluster of differentiation 45 (CD45) and cluster of differentiation 3 (CD3) expression levels and the increase in forkhead box P3 (Foxp3) levels indicate that 3,5-T2 suppresses lymphocyte recruitment. This study also showed that in HFD-T2 rats, the serum levels of irisin were increased, suggesting that this myokine could be a mechanism by which 3,5-T2 affects the inflammatory state. Additionally, to the best of our knowledge, this study reports for the first time that 3,5-T2 administration reduces the hypoxic environment induced by HFD and counteracts the DNA damage induced by oxidative stress occurring in overweight animals [ 125 ]. Most studies on 3,5-T2 effects have been conducted on animal models; therefore, the physiological effects of this metabolite on humans are still unclear, in particular, as regards the potential benefits in terms of obesity and related diseases based on the limited number of experiments performed [ 126 ]. Overall, considering the potentially beneficial effects, these results could support further studies to demonstrate the efficacy of 3,5-T2 as a therapeutic agent. The figure below illustrates a schematic representation of the effects exerted by 3,5-T2 on AT ( Figure 3 ). 10. Thyroid Hormone Metabolites and Synthetic Analogs That Act on Adipose Tissue Other natural metabolites that exert action on adipose tissue are thyronamines (TAMs). The TAMs are natural TH hormone derivatives without the carboxyl group on the alanine side chain. Nine TAMs have been described, with differences in iodine atom placement or number, but only 3-iodothyronamine (3-T1AM) and thyronamine (T0AM) have been identified in vivo [ 127 ]. 3-T1AM is found in T3 target tissues and the thyroid. However, the physiological or pathological significance of such tissues is still unknown [ 128 ]. T1AM administration in vivo has significant transcriptional effects, evident specifically in AT rather than in the liver. These effects may contribute to a reduction in fat mass and an increase in lipid metabolism [ 129 ]. Using brown adipocytes (BAs) isolated from rat BAT stromal fraction, Manuela Gencarelli et al. found that treating the cells with T1AM (M+T1AM) decreased cell lipid content, activated lipolysis, and shifted the cells into a catabolic state. According to these findings, BA long-term exposure to T1AM may ameliorate IR and obesity-related clinical conditions [ 130 ]. The subsequent oxidative deamination of iodothyronamines leads to the formation of iodothyroacetic acid derivatives [ 131 ]. Some of these metabolites, such as triiodothyroacetic acid (Triac) and tetraidothyroacetic acid (Tetrac), have been found to exert biological effects. Triac has a higher affinity for TRβ1 than T3 in various cell types including brown adipocytes [ 132 ]. An investigation performed on rats revealed that the T3 metabolite triiodothyracetic acid, at low doses, induced ectopic expression of UCP1 in abdominal WAT [ 133 ]. In addition to the naturally occurring metabolites, there are TH analogs that affect specific tissues by binding to the TR isoform in a specific manner. The most studied analog of THs that exhibits the beneficial metabolic properties of T3 is 3,5-dimethyl-4[(40-hydroxy-30-isopropylbenzyl)-phenoxy] acetic acid (GC-1). GC-1 has a high affinity for TRs and is selective in the binding and activation of TRβ over TRα [ 134 ]. Many studies have demonstrated the beneficial effects, mainly on dyslipidemia and obesity, with no unfavorable effects on the heart [ 135 , 136 ]. It has been shown that chronic administration of GC-1 to ob/ob mice resulted in marked browning of the subcutaneous WAT [ 137 ]. Noteworthy are the metabolic effects of GC-1 and mediation by WAT browning rather than an increase in BAT function, as revealed by the reduced expression of the UCP1 gene and the UCP1 protein [ 138 ]. Additionally, Lin et al. showed that chronic administration of GC-1 to obese mice markedly increased the browning of sWAT [ 138 ]. To date, little is known regarding the physiological perspective. Further research is required to comprehend the effect of such metabolites on AT physiology. 11. Conclusions The remodeling of AT is a complex but well-orchestrated mechanism that allows adaptation to external environmental changes. A deeper understanding is required to better understand the remodeling of AT towards the development of therapeutic approaches in obesity-induced metabolic disorders. The THs and certain derivatives have been found to influence relevant metabolic/physiological pathways in AT. In addition, in the last decades, numerous studies have highlighted the positive effect of such compounds on the etiology and progression of obesity-linked metabolic disorders. Our investigations offer insight into their potential use as therapeutic agents to counteract diseases such as obesity, hypercholesterolemia, hypertriglyceridemia, and IR. Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. Author Contributions Conceptualization, A.L. and R.S.; writing—original draft preparation, R.S. and G.P.; writing—review and editing, A.L., R.S., F.C. and P.d.L.; visualization, G.P. and N.M.; supervision, A.L. and R.S.; funding acquisition, A.L. and R.S. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement Not applicable. Informed Consent Statement Not applicable. Data Availability Statement Not applicable. Conflicts of Interest The authors declare no conflict of interest. Abbreviations

3,3′,5-T3 3,3′,5-Triiodothyronine 3,5,3′,5′-T4 3,5,3′,5′-Tetraiodo-L-thyronine

3,5-T2 3,5-Diiodo-L-thyronine 3-T1AM 3-Iodothyronamine

AMPK 5’ AMP-activated protein kinase APC Adipocyte progenitor cell

AT Adipose tissue ATM Adipose tissue-activated macrophages

BAT 5′D-II Type II 5′ deiodinase BAT Brown adipose tissue

BeAT Beige adipose tissue cAMP Cyclic adenosine monophosphate cBAT

Cervical brown adipose tissue Ccl2 Chemokine (C-C motif) ligand 2

CD3 Cluster of differentiation 3 CD45 Cluster of differentiation 45

CD68 Cluster of differentiation 68 COX Cytochrome c oxidase

CVD Cardiovascular disease D1 Type I deiodinase D2

Type II deiodinase D3 Type III deiodinase DIO2 Type II iodothyronine deiodinase

ECM Extracellular matrix eWAT Epidydimal white adipose tissue

F4/80 EGF-like module-containing mucin-like hormone receptor-like 1

FGF2 Fibroblast growth factor-2 Foxp3 Forkhead box P3

GC-1 (3,5-Dimethyl-4[(40-hydroxy-30-isopropylbenzyl)-phenoxy] acetic acid)

HFD High-fat diet HIF1α Hypoxia-inducible factor 1 α hMADS

Differentiated human multipotent adipose-derived stem cell

HPT Hypothalamic–pituitary–thyroid axis HSL Hormone-sensitive lipase iBAT

Interscapular brown adipose tissue IFN-c Interferon-c

IGF-I Insulin-like growth factor-I IL-10 Interleukin-10

IL-13 Interleukin-13 IL-17 Interleukin-17 IL1-β Interleukin 1-β

IL-4 Interleukin-4 IL-6 Interleukin-6 IL-8 Interleukin-8

IR Insulin resistance iWAT Inguinal white adipose tissue

LDs Lipid droplets MAPK Mitogen-activated protein kinase mBAT

Mediastinal brown adipose tissue MCP-1 Monocyte chemoattractant protein-1

MKK6 Mitogen-activated protein kinase kinase 6 MQC

Mitochondrial quality control Myf5- Myogenic factor 5- Myf5+

Myogenic factor 5+ Myh11 Myosin-heavy chain 11 NAFLD

Non-alcoholic fatty liver disease NE Norepinephrine

NRF1 Nuclear Respiratory Factor 1 NST Non-shivering thermogenesis pBAT perirenal brown adipose tissue

PGC1α Peroxisome proliferator-activated receptor-γ coactivator-1α

PPARγ Peroxisome proliferator-activated receptor γ

PRDM16 PR domain containing 16 rT3 3,3′,5′-Triiodothyronine

RXR Retinoic acid receptor sBAT Subscapular brown adipose tissue

SNS Sympathetic nervous system sWAT Subcutaneous white adipose tissue

T0AM Thyronamine T2DM Type 2 diabetes TAMs Thyronamines

Tetrac Tetraidothyroacetic acid TH Thyroid hormone

TNF-α Tumor necrosis factor α TR Thyroid hormone receptor

TRE Thyroid-hormone response element Triac Triiodothyroacetic acid

TRα Thyroid hormone receptor α TRβ Thyroid hormone receptor β

TSH Thyroid stimulating hormone UCP1 Uncoupling protein 1

VEGF-A Vascular endothelial growth factor-A vWAT Visceral adipose tissue

WAT White adipose tissue β-AR β-Adrenergic receptor References 1.

Mitchell N.S.

Catenacci V.A.

Wyatt H.R.

Hill J.O.

Obesity: Overview of an epidemic Psychiatr. Clin. North. Am. 2011 34 717 732 10.1016/j.psc.2011.08.005 22098799 PMC3228640 2.

Field A.E.

Coakley E.H.

Must A.

Spadano J.L.

Laird N.

Dietz W.H.

Rimm E.

Colditz G.A.

Impact of overweight on the risk of developing common chronic diseases during a 10-year period Arch. Intern. Med. 2001 161 1581 1586 10.1001/archinte.161.13.1581 11434789 3.

Hursting S.D.

Dunlap S.M.

Obesity, metabolic dysregulation, and cancer: A growing concern and an inflammatory (and microenvironmental) issue Ann. N. Y. Acad. Sci. 2012 1271 82 87 10.1111/j.1749-6632.2012.06737.x 23050968 PMC3485672 4.

Blokhin I.O.

Lentz S.R.

Mechanisms of thrombosis in obesity Curr. Opin. Hematol. 2013 20 437 444 10.1097/MOH.0b013e3283634443 23817170 PMC4445633 5.

Cohen P.

Spiegelman B.M.

Cell biology of fat storage Mol. Biol. Cell 2016 27 2523 2527 10.1091/mbc.e15-10-0749 27528697 PMC4985254 6.

Birsoy K.

Festuccia W.T.

Laplante M.

A comparative perspective on lipid storage in animals J. Cell Sci. 2013 126 1541 1552 10.1242/jcs.104992 23658371 7.

Sun K.

Kusminski C.M.

Scherer P.E.

Adipose tissue remodeling and obesity J. Clin. Investig. 2011 121 2094 2101 10.1172/JCI45887 21633177 PMC3104761 8.

Ruiz-Ojeda F.J.

Mendez-Gutierrez A.

Aguilera C.M.

Plaza-Diaz J.

Extracellular Matrix Remodeling of Adipose Tissue in Obesity and Metabolic Diseases Int. J. Mol. Sci. 2019 20 4888 10.3390/ijms20194888 31581657 PMC6801592 9.

Cheng L.

Wang J.

Dai H.

Duan Y.

An Y.

Shi L.

Lv Y.

Li H.

Wang C.

Ma Q.

Brown and beige adipose tissue: A novel therapeutic strategy for obesity and type 2 diabetes mellitus Adipocyte 2021 10 48 65 10.1080/21623945.2020.1870060 33403891 PMC7801117 10.

Machado S.A.

Pasquarelli-do-Nascimento G. da Silva D.S.

Farias G.R. de Oliveira Santos I.

Baptista L.B.

Magalhaes K.G.

Browning of the white adipose tissue regulation: New insights into nutritional and metabolic relevance in health and diseases Nutr. Metab. 2022 19 61 10.1186/s12986-022-00694-0 PMC9446768 36068578 11.

Item F.

Konrad D.

Visceral fat and metabolic inflammation: The portal theory revisited Obes. Rev. 2012 13 (Suppl. S2) 30 39 10.1111/j.1467-789X.2012.01035.x 23107257 12.

Vishvanath L.

Gupta R.K.

Contribution of adipogenesis to healthy adipose tissue expansion in obesity J. Clin. Investig. 2019 129 4022 4031 10.1172/JCI129191 31573549 PMC6763245 13.

Gesta S.

Tseng Y.H.

Kahn C.R.

Developmental origin of fat: Tracking obesity to its source Cell 2007 131 242 256 10.1016/j.cell.2007.10.004 17956727 14.

Cinti S.

Adipose tissues and obesity Ital. J. Anat. Embryol. 1999 104 37 51 10450668 15.

Wu J.

Bostrom P.

Sparks L.M.

Ye L.

Choi J.H.

Giang A.H.

Khandekar M.

Virtanen K.A.

Nuutila P.

Schaart G.

Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human Cell 2012 150 366 376 10.1016/j.cell.2012.05.016 22796012 PMC3402601 16.

Huh J.Y.

Park Y.J.

Ham M.

Kim J.B.

Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity Mol. Cells 2014 37 365 371 10.14348/molcells.2014.0074 24781408 PMC4044307 17.

Sakers A.

De Siqueira M.K.

Seale P.

Villanueva C.J.

Adipose-tissue plasticity in health and disease Cell 2022 185 419 446 10.1016/j.cell.2021.12.016 35120662 PMC11152570 18.

Saponaro C.

Gaggini M.

Carli F.

Gastaldelli A.

The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis Nutrients 2015 7 9453 9474 10.3390/nu7115475 26580649 PMC4663603 19.

Fasshauer M.

Bluher M.

Adipokines in health and disease Trends Pharmacol. Sci. 2015 36 461 470 10.1016/j.tips.2015.04.014 26022934 20.

Huang Z.

Xu A.

Adipose Extracellular Vesicles in Intercellular and Inter-Organ Crosstalk in Metabolic Health and Diseases Front. Immunol. 2021 12 608680 10.3389/fimmu.2021.608680 33717092 PMC7946830 21.

Lopez-Jaramillo P.

Gomez-Arbelaez D.

Lopez-Lopez J.

Lopez-Lopez C.

Martinez-Ortega J.

Gomez-Rodriguez A.

Triana-Cubillos S.

The role of leptin/adiponectin ratio in metabolic syndrome and diabetes Horm. Mol. Biol. Clin. Investig. 2014 18 37 45 10.1515/hmbci-2013-0053 25389999 22.

Lackey D.E.

Olefsky J.M.

Regulation of metabolism by the innate immune system Nat. Rev. Endocrinol. 2016 12 15 28 10.1038/nrendo.2015.189 26553134 23.

Virtue S.

Vidal-Puig A.

Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—An allostatic perspective Biochim. Biophys. Acta 2010 1801 338 349 10.1016/j.bbalip.2009.12.006 20056169 24.

Sun W. von Meyenn F.

Peleg-Raibstein D.

Wolfrum C.

Environmental and Nutritional Effects Regulating Adipose Tissue Function and Metabolism Across Generations Adv. Sci. 2019 6 1900275 10.1002/advs.201900275 31179229 PMC6548959 25.

Al-Mansoori L.

Al-Jaber H.

Prince M.S.

Elrayess M.A.

Role of Inflammatory Cytokines, Growth Factors and Adipokines in Adipogenesis and Insulin Resistance Inflammation 2022 45 31 44 10.1007/s10753-021-01559-z 34536157 PMC8449520 26.

Hirosumi J.

Tuncman G.

Chang L.

Gorgun C.Z.

Uysal K.T.

Maeda K.

Karin M.

Hotamisligil G.S.

A central role for JNK in obesity and insulin resistance Nature 2002 420 333 336 10.1038/nature01137 12447443 27.

Pirola L.

Ferraz J.C.

Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity World J. Biol. Chem. 2017 8 120 128 10.4331/wjbc.v8.i2.120 28588755 PMC5439163 28.

Lee Y.S.

Kim J.W.

Osborne O.

Oh D.Y.

Sasik R.

Schenk S.

Chen A.

Chung H.

Murphy A.

Watkins S.M.

Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity Cell 2014 157 1339 1352 10.1016/j.cell.2014.05.012 24906151 PMC4114226 29.

Ruggiero A.D.

Key C.C.

Kavanagh K.

Adipose Tissue Macrophage Polarization in Healthy and Unhealthy Obesity Front. Nutr. 2021 8 625331 10.3389/fnut.2021.625331 33681276 PMC7925825 30.

Zatterale F.

Longo M.

Naderi J.

Raciti G.A.

Desiderio A.

Miele C.

Beguinot F.

Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes Front. Physiol. 2019 10 1607 10.3389/fphys.2019.01607 32063863 PMC7000657 31.

Lumeng C.N.

Bodzin J.L.

Saltiel A.R.

Obesity induces a phenotypic switch in adipose tissue macrophage polarization J. Clin. Investig. 2007 117 175 184 10.1172/JCI29881 17200717 PMC1716210 32.

Subramanian V.

Ferrante A.W. Jr.

Obesity, inflammation, and macrophages Nestle Nutr. Workshop Ser. Pediatr. Program. 2009 63 151 259 151–159; discussion 159–162, 168–259 10.1159/000209979 19346774 33.

McLaughlin T.

Ackerman S.E.

Shen L.

Engleman E.

Role of innate and adaptive immunity in obesity-associated metabolic disease J. Clin. Investig. 2017 127 5 13 10.1172/JCI88876 28045397 PMC5199693 34.

Sica A.

Mantovani A.

Macrophage plasticity and polarization: In vivo veritas J. Clin. Investig. 2012 122 787 795 10.1172/JCI59643 22378047 PMC3287223 35.

Mosser D.M.

The many faces of macrophage activation J. Leukoc. Biol. 2003 73 209 212 10.1189/jlb.0602325 12554797 36.

Fujisaka S.

The role of adipose tissue M1/M2 macrophages in type 2 diabetes mellitus Diabetol. Int. 2021 12 74 79 10.1007/s13340-020-00482-2 33479582 PMC7790922 37.

Nedergaard J.

Bengtsson T.

Cannon B.

Unexpected evidence for active brown adipose tissue in adult humans Am. J. Physiol. Endocrinol. Metab. 2007 293 E444 E452 10.1152/ajpendo.00691.2006 17473055 38.

Frontini A.

Cinti S.

Distribution and development of brown adipocytes in the murine and human adipose organ Cell. Metab. 2010 11 253 256 10.1016/j.cmet.2010.03.004 20374956 39.

Ikeda K.

Yamada T.

UCP1 Dependent and Independent Thermogenesis in Brown and Beige Adipocytes Front. Endocrinol. 2020 11 498 10.3389/fendo.2020.00498 PMC7399049 32849287 40.

Lepper C.

Fan C.M.

Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells Genesis 2010 48 424 436 10.1002/dvg.20630 20641127 PMC3113517 41.

Farmer S.R.

Brown fat and skeletal muscle: Unlikely cousins? Cell. 2008 134 726 727 10.1016/j.cell.2008.08.018 18775306 42.

Alcala M.

Calderon-Dominguez M.

Bustos E.

Ramos P.

Casals N.

Serra D.

Viana M.

Herrero L.

Increased inflammation, oxidative stress and mitochondrial respiration in brown adipose tissue from obese mice Sci. Rep. 2017 7 16082 10.1038/s41598-017-16463-6 29167565 PMC5700117 43.

Bartelt A.

Merkel M.

Heeren J.

A new, powerful player in lipoprotein metabolism: Brown adipose tissue J. Mol. Med. 2012 90 887 893 10.1007/s00109-012-0858-3 22231746 44.

Villarroya J.

Cereijo R.

Villarroya F.

An endocrine role for brown adipose tissue? Am. J. Physiol. Endocrinol. Metab. 2013 305 E567 E572 10.1152/ajpendo.00250.2013 23839524 45.

Lee E.H.

Chun S.Y.

Lee J.N.

Chung J.W.

Yoon B.H.

Kim H.T.

Kwon T.G.

Ha Y.S.

Kim B.S.

Perirenal Adipose Tissue from Healthy Donor: Characteristics and Promise as Potential Therapeutic Cell Source J. Clin. Med. 2021 10 5024 10.3390/jcm10215024 34768543 PMC8585005 46.

Silva J.E.

Larsen P.R.

Adrenergic activation of triiodothyronine production in brown adipose tissue Nature 1983 305 712 713 10.1038/305712a0 6633638 47.

Fitzgibbons T.P.

Kogan S.

Aouadi M.

Hendricks G.M.

Straubhaar J.

Czech M.P.

Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation Am. J. Physiol. Heart Circ. Physiol. 2011 301 H1425 H1437 10.1152/ajpheart.00376.2011 21765057 PMC3197360 48.

Sakamoto T.

Nitta T.

Maruno K.

Yeh Y.S.

Kuwata H.

Tomita K.

Goto T.

Takahashi N.

Kawada T.

Macrophage infiltration into obese adipose tissues suppresses the induction of UCP1 level in mice Am. J. Physiol. Endocrinol. Metab. 2016 310 E676 E687 10.1152/ajpendo.00028.2015 26884382 49.

Roberts-Toler C.

O’Neill B.T.

Cypess A.M.

Diet-induced obesity causes insulin resistance in mouse brown adipose tissue Obesity 2015 23 1765 1770 10.1002/oby.21134 26242777 PMC4551605 50.

Harms M.

Seale P.

Brown and beige fat: Development, function and therapeutic potential Nat. Med. 2013 19 1252 1263 10.1038/nm.3361 24100998 51.

Long J.Z.

Svensson K.J.

Tsai L.

Zeng X.

Roh H.C.

Kong X.

Rao R.R.

Lou J.

Lokurkar I.

Baur W.

A smooth muscle-like origin for beige adipocytes Cell Metab. 2014 19 810 820 10.1016/j.cmet.2014.03.025 24709624 PMC4052772 52.

Frontini A.

Vitali A.

Perugini J.

Murano I.

Romiti C.

Ricquier D.

Guerrieri M.

Cinti S.

White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma Biochim. Biophys. Acta 2013 1831 950 959 10.1016/j.bbalip.2013.02.005 23454374 53.

Tran K.V.

Gealekman O.

Frontini A.

Zingaretti M.C.

Morroni M.

Giordano A.

Smorlesi A.

Perugini J.

De Matteis R.

Sbarbati A.

The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells Cell Metab. 2012 15 222 229 10.1016/j.cmet.2012.01.008 22326223 PMC3278718 54.

Lee Y.H.

Petkova A.P.

Konkar A.A.

Granneman J.G.

Cellular origins of cold-induced brown adipocytes in adult mice FASEB J. 2015 29 286 299 10.1096/fj.14-263038 25392270 PMC4285542 55.

Wang Q.A.

Tao C.

Gupta R.K.

Scherer P.E.

Tracking adipogenesis during white adipose tissue development, expansion and regeneration Nat. Med. 2013 19 1338 1344 10.1038/nm.3324 23995282 PMC4075943 56.

Rosenwald M.

Perdikari A.

Rulicke T.

Wolfrum C.

Bi-directional interconversion of brite and white adipocytes Nat. Cell Biol. 2013 15 659 667 10.1038/ncb2740 23624403 57.

Esteve D.

Boulet N.

Volat F.

Zakaroff-Girard A.

Ledoux S.

Coupaye M.

Decaunes P.

Belles C.

Gaits-Iacovoni F.

Iacovoni J.S.

Human white and brite adipogenesis is supported by MSCA1 and is impaired by immune cells Stem Cells 2015 33 1277 1291 10.1002/stem.1916 25523907 58.

Cohen P.

Levy J.D.

Zhang Y.

Frontini A.

Kolodin D.P.

Svensson K.J.

Lo J.C.

Zeng X.

Ye L.

Khandekar M.J.

Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch Cell 2014 156 304 316 10.1016/j.cell.2013.12.021 24439384 PMC3922400 59.

Lim S.

Honek J.

Xue Y.

Seki T.

Cao Z.

Andersson P.

Yang X.

Hosaka K.

Cao Y.

Cold-induced activation of brown adipose tissue and adipose angiogenesis in mice Nat. Protoc. 2012 7 606 615 10.1038/nprot.2012.013 22383039 60.

Xiao C.

Goldgof M.

Gavrilova O.

Reitman M.L.

Anti-obesity and metabolic efficacy of the beta3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22 degrees C Obesity 2015 23 1450 1459 10.1002/oby.21124 26053335 PMC4482793 61.

Yao L.

Cui X.

Chen Q.

Yang X.

Fang F.

Zhang J.

Liu G.

Jin W.

Chang Y.

Cold-Inducible SIRT6 Regulates Thermogenesis of Brown and Beige Fat Cell. Rep. 2017 20 641 654 10.1016/j.celrep.2017.06.069 28723567 62. de Jong J.M.A.

Wouters R.T.F.

Boulet N.

Cannon B.

Nedergaard J.

Petrovic N.

The beta(3)-adrenergic receptor is dispensable for browning of adipose tissues Am. J. Physiol. Endocrinol. Metab. 2017 312 E508 E518 10.1152/ajpendo.00437.2016 28223294 63.

Cinti S.

Pink Adipocytes Trends Endocrinol. Metab. 2018 29 651 666 10.1016/j.tem.2018.05.007 30017740 64.

Giordano A.

Smorlesi A.

Frontini A.

Barbatelli G.

Cinti S.

White, brown and pink adipocytes: The extraordinary plasticity of the adipose organ Eur. J. Endocrinol. 2014 170 R159 R171 10.1530/EJE-13-0945 24468979 65.

Giordano A.

Perugini J.

Kristensen D.M.

Sartini L.

Frontini A.

Kajimura S.

Kristiansen K.

Cinti S.

Mammary alveolar epithelial cells convert to brown adipocytes in post-lactating mice J. Cell. Physiol. 2017 232 2923 2928 10.1002/jcp.25858 28191637 PMC5526734 66.

Halperin Y.

Shapiro L.E.

Surks M.I.

Medium 3,5,3′-triiodo-L-thyronine (T3) and T3 generated from L-thyroxine are exchangeable in cultured GC cells Endocrinology 1990 127 1050 1056 10.1210/endo-127-3-1050 2387247 67.

Ortiga-Carvalho T.M.

Chiamolera M.I.

Pazos-Moura C.C.

Wondisford F.E.

Hypothalamus-Pituitary-Thyroid Axis Compr. Physiol. 2016 6 1387 1428 10.1002/cphy.c150027 27347897 68.

Davis P.J.

Goglia F.

Leonard J.L.

Nongenomic actions of thyroid hormone Nat. Rev. Endocrinol. 2016 12 111 121 10.1038/nrendo.2015.205 26668118 69.

Lanni A.

Moreno M.

Goglia F.

Mitochondrial Actions of Thyroid Hormone Compr. Physiol. 2016 6 1591 1607 10.1002/cphy.c150019 27783852 70.

Goglia F.

Moreno M.

Lanni A.

Action of thyroid hormones at the cellular level: The mitochondrial target FEBS Lett. 1999 452 115 120 10.1016/S0014-5793(99)00642-0 10386574 71.

Wrutniak-Cabello C.

Casas F.

Cabello G.

Thyroid hormone action in mitochondria J. Mol. Endocrinol. 2001 26 67 77 10.1677/jme.0.0260067 11174855 72.

Wrutniak-Cabello C.

Carazo A.

Casas F.

Cabello G.

Triiodothyronine mitochondrial receptors: Import and molecular mechanisms J. Soc. Biol. 2008 202 83 92 10.1051/jbio:2008010 18547504 73.

Cioffi F.

Senese R.

Lanni A.

Goglia F.

Thyroid hormones and mitochondria: With a brief look at derivatives and analogues Mol. Cell. Endocrinol. 2013 379 51 61 10.1016/j.mce.2013.06.006 23769708 74.

Bergh J.J.

Lin H.Y.

Lansing L.

Mohamed S.N.

Davis F.B.

Mousa S.

Davis P.J.

Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis Endocrinology 2005 146 2864 2871 10.1210/en.2005-0102 15802494 75.

Davis P.J.

Lin H.Y.

Mousa S.A.

Luidens M.K.

Hercbergs A.A.

Wehling M.

Davis F.B.

Overlapping nongenomic and genomic actions of thyroid hormone and steroids Steroids 2011 76 829 833 10.1016/j.steroids.2011.02.012 21354437 76.

Obregon M.J.

Adipose tissues and thyroid hormones Front. Physiol. 2014 5 479 10.3389/fphys.2014.00479 25566082 PMC4263094 77.

Panveloski-Costa A.C.

Serrano-Nascimento C.

Bargi-Souza P.

Poyares L.L.

Viana G.S.

Nunes M.T.

Beneficial effects of thyroid hormone on adipose inflammation and insulin sensitivity of obese Wistar rats Physiol. Rep. 2018 6 e13550 10.14814/phy2.13550 29388360 PMC5817825 78.

Panveloski-Costa A.C.

Silva Teixeira S.

Ribeiro I.M.

Serrano-Nascimento C. das Neves R.X.

Favaro R.R.

Seelaender M.

Antunes V.R.

Nunes M.T.

Thyroid hormone reduces inflammatory cytokines improving glycaemia control in alloxan-induced diabetic wistar rats Acta Physiol. 2016 217 130 140 10.1111/apha.12647 26748816 79.

Bianco A.C.

McAninch E.A.

The role of thyroid hormone and brown adipose tissue in energy homoeostasis Lancet Diabetes Endocrinol. 2013 1 250 258 10.1016/S2213-8587(13)70069-X 24622373 PMC4976626 80.

Silva J.E.

The multiple contributions of thyroid hormone to heat production J. Clin. Investig. 2001 108 35 37 10.1172/JCI200113397 11435454 PMC209345 81.

Silva J.E.

Thermogenic mechanisms and their hormonal regulation Physiol. Rev. 2006 86 435 464 10.1152/physrev.00009.2005 16601266 82.

Ribeiro M.O.

Bianco S.D.

Kaneshige M.

Schultz J.J.

Cheng S.Y.

Bianco A.C.

Brent G.A.

Expression of Uncoupling Protein 1 in Mouse Brown Adipose Tissue Is Thyroid Hormone Receptor-β Isoform Specific and Required for Adaptive Thermogenesis Endocrinology 1 January 2010 151 432 440 10.1210/en.2009-0667 19906816 PMC2817565 83.

Alvarez-Crespo M.

Csikasz R.I.

Martinez-Sanchez N.

Dieguez C.

Cannon B.

Nedergaard J.

Lopez M.

Essential role of UCP1 modulating the central effects of thyroid hormones on energy balance Mol. Metab. 2016 5 271 282 10.1016/j.molmet.2016.01.008 27069867 PMC4812006 84.

Martinez-Sanchez N.

Moreno-Navarrete J.M.

Contreras C.

Rial-Pensado E.

Ferno J.

Nogueiras R.

Dieguez C.

Fernandez-Real J.M.

Lopez M.

Thyroid hormones induce browning of white fat J. Endocrinol. 2017 232 351 362 10.1530/JOE-16-0425 27913573 PMC5292977 85.

Bianco A.C.

Maia A.L. da Silva W.S.

Christoffolete M.A.

Adaptive activation of thyroid hormone and energy expenditure Biosci. Rep. 2005 25 191 208 10.1007/s10540-005-2885-6 16283553 86.

Martinez-Sanchez N.

Alvarez C.V.

Ferno J.

Nogueiras R.

Dieguez C.

Lopez M.

Hypothalamic effects of thyroid hormones on metabolism Best. Pract. Res. Clin. Endocrinol. Metab. 2014 28 703 712 10.1016/j.beem.2014.04.004 25256765 87.

Cheng S.Y.

Leonard J.L.

Davis P.J.

Molecular aspects of thyroid hormone actions Endocr. Rev. 2010 31 139 170 10.1210/er.2009-0007 20051527 PMC2852208 88.

Oetting A.

Yen P.M.

New insights into thyroid hormone action Best. Pract. Res. Clin. Endocrinol. Metab. 2007 21 193 208 10.1016/j.beem.2007.04.004 17574003 89.

Hollenberg A.N.

Monden T.

Wondisford F.E.

Ligand-independent and -dependent functions of thyroid hormone receptor isoforms depend upon their distinct amino termini J. Biol. Chem. 1995 270 14274 14280 10.1074/jbc.270.24.14274 7782283 90.

Ribeiro M.O.

Carvalho S.D.

Schultz J.J.

Chiellini G.

Scanlan T.S.

Bianco A.C.

Brent G.A.

Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific J. Clin. Investig. 2001 108 97 105 10.1172/JCI200112584 11435461 PMC209342 91.

Bianco A.C.

Silva J.E.

Nuclear 3,5,3′-triiodothyronine (T3) in brown adipose tissue: Receptor occupancy and sources of T3 as determined by in vivo techniques Endocrinology 1987 120 55 62 10.1210/endo-120-1-55 3780570 92.

Christoffolete M.A.

Linardi C.C. de Jesus L.

Ebina K.N.

Carvalho S.D.

Ribeiro M.O.

Rabelo R.

Curcio C.

Martins L.

Kimura E.T.

Mice with targeted disruption of the Dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis Diabetes 2004 53 577 584 10.2337/diabetes.53.3.577 14988240 93.

Mottillo E.P.

Desjardins E.M.

Crane J.D.

Smith B.K.

Green A.E.

Ducommun S.

Henriksen T.I.

Rebalka I.A.

Razi A.

Sakamoto K.

Lack of Adipocyte AMPK Exacerbates Insulin Resistance and Hepatic Steatosis through Brown and Beige Adipose Tissue Function Cell Metab. 2016 24 118 129 10.1016/j.cmet.2016.06.006 27411013 PMC5239668 94.

Martinez-Lopez N.

Garcia-Macia M.

Sahu S.

Athonvarangkul D.

Liebling E.

Merlo P.

Cecconi F.

Schwartz G.J.

Singh R.

Autophagy in the CNS and Periphery Coordinate Lipophagy and Lipolysis in the Brown Adipose Tissue and Liver Cell Metab. 2016 23 113 127 10.1016/j.cmet.2015.10.008 26698918 PMC4715637 95.

Yau W.W.

Singh B.K.

Lesmana R.

Zhou J.

Sinha R.A.

Wong K.A.

Wu Y.

Bay B.H.

Sugii S.

Sun L.

Thyroid hormone (T(3)) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy Autophagy 2019 15 131 150 10.1080/15548627.2018.1511263 30209975 PMC6287687 96.

Masini M.

De Tata V.

Del Roso A.

Simonetti I.

Pollera M.

Bergamini E.

The brown adipose tissue of hyperthyroid rats. A biochemical and ultrastructural study Mol. Cell. Endocrinol. 1990 73 27 34 10.1016/0303-7207(90)90041-6 2292337 97.

Liu S.

Shen S.

Yan Y.

Sun C.

Lu Z.

Feng H.

Ma Y.

Tang Z.

Yu J.

Wu Y.

Triiodothyronine (T3) promotes brown fat hyperplasia via thyroid hormone receptor alpha mediated adipocyte progenitor cell proliferation Nat. Commun. 2022 13 3394 10.1038/s41467-022-31154-1 35697700 PMC9192766 98.

Lee J.Y.

Takahashi N.

Yasubuchi M.

Kim Y.I.

Hashizaki H.

Kim M.J.

Sakamoto T.

Goto T.

Kawada T.

Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes Am. J. Physiol. Cell Physiol. 2012 302 C463 C472 10.1152/ajpcell.00010.2011 22075692 99.

Matesanz N.

Bernardo E.

Acin-Perez R.

Manieri E.

Perez-Sieira S.

Hernandez-Cosido L.

Montalvo-Romeral V.

Mora A.

Rodriguez E.

Leiva-Vega L.

MKK6 controls T3-mediated browning of white adipose tissue Nat. Commun. 2017 8 856 10.1038/s41467-017-00948-z 29021624 PMC5636784 100. de Oliveira M.

Mathias L.S.

Rodrigues B.M.

Mariani B.G.

Graceli J.B.

De Sibio M.T.

Castro Olimpio R.M.

Fontes Moretto F.C.

Depra I.C.

Nogueira C.R.

The roles of triiodothyronine and irisin in improving the lipid profile and directing the browning of human adipose subcutaneous cells Mol. Cell Endocrinol. 2020 506 110744 10.1016/j.mce.2020.110744 32027943 101.

Ma Y.

Shen S.

Yan Y.

Zhang S.

Liu S.

Tang Z.

Yu J.

Ma M.

Niu Z.

Li Z.

Adipocyte thyroid hormone beta receptor-mediated hormone action fine-tunes the intracellular glucose and lipid metabolism and systemic homeostasis Diabetes 2023 db220656 10.2337/db22-0656 36724137 102.

Senese R. de Lange P.

Petito G.

Moreno M.

Goglia F.

Lanni A.

3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism Front. Endocrinol. 2018 9 427 10.3389/fendo.2018.00427 30090086 PMC6068267 103.

Senese R.

Cioffi F.

Petito G.

Goglia F.

Lanni A.

Thyroid hormone metabolites and analogues Endocrine 2019 66 105 114 10.1007/s12020-019-02025-5 31359245 104.

Goglia F.

Biological effects of 3,5-diiodothyronine (T(2)) Biochemistry 2005 70 164 172 10.1007/s10541-005-0097-0 15807655 105.

Goglia F.

The effects of 3,5-diiodothyronine on energy balance Front. Physiol. 2014 5 528 10.3389/fphys.2014.00528 25628573 PMC4292545 106.

Kohrle J.

The Colorful Diversity of Thyroid Hormone Metabolites Eur. Thyroid. J. 2019 8 115 129 10.1159/000497141 31259154 PMC6587369 107.

Moreno M.

Giacco A.

Di Munno C.

Goglia F.

Direct and rapid effects of 3,5-diiodo-L-thyronine (T2) Mol. Cell Endocrinol. 2017 458 121 126 10.1016/j.mce.2017.02.012 28192176 108.

Padron A.S.

Neto R.A.

Pantaleao T.U. de Souza dos Santos M.C.

Araujo R.L. de Andrade B.M. da Silva Leandro M. de Castro J.P.

Ferreira A.C. de Carvalho D.P.

Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues J. Endocrinol. 2014 221 415 427 10.1530/JOE-13-0502 24692290 PMC4045230 109.

Jonas W.

Lietzow J.

Wohlgemuth F.

Hoefig C.S.

Wiedmer P.

Schweizer U.

Kohrle J.

Schurmann A.

3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice Endocrinology 2015 156 389 399 10.1210/en.2014-1604 25322465 PMC4272399 110.

Louzada R.A.

Carvalho D.P.

Similarities and Differences in the Peripheral Actions of Thyroid Hormones and Their Metabolites Front. Endocrinol. 2018 9 394 10.3389/fendo.2018.00394 PMC6060242 30072951 111.

Sacripanti G.

Nguyen N.M.

Lorenzini L.

Frascarelli S.

Saba A.

Zucchi R.

Ghelardoni S.

3,5-Diiodo-l-Thyronine Increases Glucose Consumption in Cardiomyoblasts Without Affecting the Contractile Performance in Rat Heart Front. Endocrinol. 2018 9 282 10.3389/fendo.2018.00282 29899732 PMC5988897 112.

Moreno M.

Lombardi A.

Beneduce L.

Silvestri E.

Pinna G.

Goglia F.

Lanni A.

Are the effects of T3 on resting metabolic rate in euthyroid rats entirely caused by T3 itself? Endocrinology 2002 143 504 510 10.1210/endo.143.2.8613 11796504 113.

Lanni A.

Moreno M.

Lombardi A.

Goglia F.

3,5-Diiodo-L-thyronine and 3,5,3′-triiodo-L-thyronine both improve the cold tolerance of hypothyroid rats, but possibly via different mechanisms Pflugers Arch. 1998 436 407 414 10.1007/s004240050650 9644223 114.

Silvestri E.

Lombardi A.

Coppola M.

Gentile A.

Cioffi F.

Senese R.

Goglia F.

Lanni A.

Moreno M. de Lange P.

Differential Effects of 3,5-Diiodo-L-Thyronine and 3,5,3′-Triiodo-L-Thyronine On Mitochondrial Respiratory Pathways in Liver from Hypothyroid Rats Cell. Physiol. Biochem. 2018 47 2471 2483 10.1159/000491620 29990992 115.

Lanni A.

Moreno M.

Lombardi A. de Lange P.

Silvestri E.

Ragni M.

Farina P.

Baccari G.C.

Fallahi P.

Antonelli A.

3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats FASEB J. 2005 19 1552 1554 10.1096/fj.05-3977fje 16014396 116. de Lange P.

Cioffi F.

Senese R.

Moreno M.

Lombardi A.

Silvestri E.

De Matteis R.

Lionetti L.

Mollica M.P.

Goglia F.

Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats Diabetes 2011 60 2730 2739 10.2337/db11-0207 21926273 PMC3198093 117.

Silvestri E.

Cioffi F.

Glinni D.

Ceccarelli M.

Lombardi A. de Lange P.

Chambery A.

Severino V.

Lanni A.

Goglia F.

Pathways affected by 3,5-diiodo-l-thyronine in liver of high fat-fed rats: Evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry Mol. Biosyst. 2010 6 2256 2271 10.1039/c0mb00040j 20844788 118.

Moreno M.

Silvestri E.

De Matteis R. de Lange P.

Lombardi A.

Glinni D.

Senese R.

Cioffi F.

Salzano A.M.

Scaloni A.

3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations FASEB J. 2011 25 3312 3324 10.1096/fj.11-181982 21670063 119.

Cioffi F.

Gentile A.

Silvestri E.

Goglia F.

Lombardi A.

Effect of Iodothyronines on Thermogenesis: Focus on Brown Adipose Tissue Front. Endocrinol. 2018 9 254 10.3389/fendo.2018.00254 29875734 PMC5974034 120.

Lombardi A.

Senese R.

De Matteis R.

Busiello R.A.

Cioffi F.

Goglia F.

Lanni A.

3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats PLoS ONE 2015 10 e0116498 10.1371/journal.pone.0116498 25658324 PMC4319745 121.

Fredriksson J.M.

Lindquist J.M.

Bronnikov G.E.

Nedergaard J.

Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2 J. Biol. Chem. 2000 275 13802 13811 10.1074/jbc.275.18.13802 10788502 122.

Senese R.

Cioffi F.

De Matteis R.

Petito G. de Lange P.

Silvestri E.

Lombardi A.

Moreno M.

Goglia F.

Lanni A.

3,5 Diiodo-l-Thyronine (T(2)) Promotes the Browning of White Adipose Tissue in High-Fat Diet-Induced Overweight Male Rats Housed at Thermoneutrality Cells 2019 8 256 10.3390/cells8030256 30889829 PMC6468521 123.

Reyes-Farias M.

Fos-Domenech J.

Serra D.

Herrero L.

Sanchez-Infantes D.

White adipose tissue dysfunction in obesity and aging Biochem. Pharmacol. 2021 192 114723 10.1016/j.bcp.2021.114723 34364887 124.

Silvestri E.

Senese R.

Cioffi F.

De Matteis R.

Lattanzi D.

Lombardi A.

Giacco A.

Salzano A.M.

Scaloni A.

Ceccarelli M.

3,5-Diiodo-L-Thyronine Exerts Metabolically Favorable Effects on Visceral Adipose Tissue of Rats Receiving a High-Fat Diet Nutrients 2019 11 278 10.3390/nu11020278 30691227 PMC6412262 125.

Petito G.

Cioffi F.

Silvestri E.

De Matteis R.

Lattanzi D. de Lange P.

Lombardi A.

Moreno M.

Goglia F.

Lanni A.

3,5-Diiodo-L-Thyronine (T2) Administration Affects Visceral Adipose Tissue Inflammatory State in Rats Receiving Long-Lasting High-Fat Diet Front. Endocrinol. 2021 12 703170 10.3389/fendo.2021.703170 34322094 PMC8312549 126.

Lehmphul I.

Brabant G.

Wallaschofski H.

Ruchala M.

Strasburger C.J.

Kohrle J.

Wu Z.

Detection of 3,5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay Thyroid 2014 24 1350 1360 10.1089/thy.2013.0688 24967815 127.

Piehl S.

Hoefig C.S.

Scanlan T.S.

Kohrle J.

Thyronamines--past, present, and future Endocr. Rev. 2011 32 64 80 10.1210/er.2009-0040 20880963 128.

Scanlan T.S.

Minireview: 3-Iodothyronamine (T1AM): A new player on the thyroid endocrine team? Endocrinology 2009 150 1108 1111 10.1210/en.2008-1596 19116337 PMC2654747 129.

Mariotti V.

Melissari E.

Iofrida C.

Righi M.

Di Russo M.

Donzelli R.

Saba A.

Frascarelli S.

Chiellini G.

Zucchi R.

Modulation of gene expression by 3-iodothyronamine: Genetic evidence for a lipolytic pattern PLoS ONE 2014 9 e106923 10.1371/journal.pone.0106923 25379707 PMC4224367 130.

Gencarelli M.

Laurino A.

Landucci E.

Buonvicino D.

Mazzantini C.

Chiellini G.

Raimondi L.

3-Iodothyronamine Affects Thermogenic Substrates’ Mobilization in Brown Adipocytes Biology 2020 9 95 10.3390/biology9050095 32375297 PMC7285105 131.

Wood W.J.

Geraci T.

Nilsen A.

DeBarber A.E.

Scanlan T.S.

Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo Chembiochem 2009 10 361 365 10.1002/cbic.200800607 19105176 PMC4086354 132.

Schueler P.A.

Schwartz H.L.

Strait K.A.

Mariash C.N.

Oppenheimer J.H.

Binding of 3,5,3′-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: Differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3 Mol. Endocrinol. 1990 4 227 234 10.1210/mend-4-2-227 2158622 133.

Medina-Gomez G.

Calvo R.M.

Obregon M.J.

Thermogenic effect of triiodothyroacetic acid at low doses in rat adipose tissue without adverse side effects in the thyroid axis Am. J. Physiol. Endocrinol. Metab. 2008 294 E688 E697 10.1152/ajpendo.00417.2007 18285526 134.

Chiellini G.

Apriletti J.W.

Yoshihara H.A.

Baxter J.D.

Ribeiro R.C.

Scanlan T.S.

A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor Chem. Biol. 1998 5 299 306 10.1016/S1074-5521(98)90168-5 9653548 135.

Baxter J.D.

Webb P.

Grover G.

Scanlan T.S.

Selective activation of thyroid hormone signaling pathways by GC-1: A new approach to controlling cholesterol and body weight Trends Endocrinol. Metab. 2004 15 154 157 10.1016/j.tem.2004.03.008 15109613 136.

Grover G.J.

Egan D.M.

Sleph P.G.

Beehler B.C.

Chiellini G.

Nguyen N.H.

Baxter J.D.

Scanlan T.S.

Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: Selective actions relative to 3,5,3′-triiodo-L-thyronine Endocrinology 2004 145 1656 1661 10.1210/en.2003-0973 14701670 137.

Villicev C.M.

Freitas F.R.

Aoki M.S.

Taffarel C.

Scanlan T.S.

Moriscot A.S.

Ribeiro M.O.

Bianco A.C.

Gouveia C.H.

Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats J. Endocrinol. 2007 193 21 29 10.1677/joe.1.07066 17400799 138.

Lin J.Z.

Martagon A.J.

Cimini S.L.

Gonzalez D.D.

Tinkey D.W.

Biter A.

Baxter J.D.

Webb P.

Gustafsson J.A.

Hartig S.M.

Pharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown Fat Cell. Rep. 2015 13 1528 1537 10.1016/j.celrep.2015.10.022 26586443 PMC4662916 Figure 1 Adipose tissue distribution. ( A ) Distribution of WAT and BAT in humans. Both vWAT and sWAT possess abilities to store energy and secrete various adipokines. The sWAT is distributed throughout the body under the skin, while the vWAT surrounds the intra-abdominal organs. Located around the shoulders and ribs, BAT contributes to heat generation through the expression of UCP-1. ( B ) As compared to adult humans, the BAT in adult mice is well developed and easy to observe. The gonadal WAT depots located around the ovaries and the testes are studied as a model of vWAT. The figure was created with Biorender.com.( https://www.biorender.com/ Accessed on 16 May 2022). Figure 2 Thermogenic control of brown adipocytes by UCP1. Sympathetic neurons release synaptic norepinephrine that binds to β-adrenergic receptors, stimulating the production of cAMP by adenylate cyclase. The sympathetic signal activates transcription factors and coactivators involved in the regulation of DIO 2. Both adrenergic signaling and TRs regulate UCP1 expression. Lipases break down triglycerides into free fatty acids, which are then transported to mitochondria and activate UCP1. UCP1 uncouples ATP production from respiration, causing an increase in mitochondrial activity and generating heat. The figure was created with Biorender.com. Figure 3 ( A ) In hypothyroid rats housed at thermoneutrality, 3,5-T2 increases multilocular versus unilocular cells, decreases LD diameter, and increases mitochondrial content, indicating BAT activation. Diiodothyronine also increases the cellular number of nerve fibers and vascularization, suggesting that part of the thermogenic effect induced by 3,5-T2 in BAT is due to SNS activation. ( B ) Browning process in a section of anterior sWAT of HFD-T2 rats in which several white adipocytes undergo phenotypic change. The adipocyte acquires a multilocular phenotype as an alternative to the conventional unilocular phenotype, with high levels of UCP1. This process involves different pathways, including microRNAs (e.g., miR-133a and miR-196a) and irisin. ( C ) Schematic representation of the effects exerted on adipocytes in vWAT by HFD for 14 weeks and by HFD for 14 weeks and 3,5-T2 administered daily during the last 4 weeks (HFD-T2). In vWAT from overweight rats, hypoxia induces the synthesis of several angiogenic factors (e.g., VEGF-A) and the expression of inflammatory cytokines (e.g., TNF-α, IL-6). Accordingly, a vicious circle is established in which the activation of angiogenesis first determines a further increase in adipocyte volume, thus enhancing an increase in the inflammatory state of the AT. In overweight rats treated with 3,5-T2, the inflammatory state is reverted. Diiodothyronine can reduce hypoxia, angiogenesis, and inflammatory agents. The figure was created with Biorender.com.